News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
ALI HEALTH Partners with Merson Pharmaceutical to Launch World's 1st New Topical Medication for Infantile Hemangioma
ALI HEALTH (00241.HK)] and Beijing Merson Pharmaceutical announced a strategic partnership to launch in-depth collaboration in pediatric specialty innovative drugs, promoting the o...
Reset
Send
The window will close in 5 seconds
ALI HEALTH Partners with Merson Pharmaceutical to Launch World's 1st New Topical Medication for Infantile Hemangioma
Close
Recommend
20
Positive
32
Negative
9
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

ALI HEALTH (00241.HK)  -0.070 (-1.461%)    Short selling $109.33M; Ratio 72.778%   ] and Beijing Merson Pharmaceutical announced a strategic partnership to launch in-depth collaboration in pediatric specialty innovative drugs, promoting the omnichannel launch of timolol maleate gel, the world's first approved topical innovative drug for treating proliferative superficial infantile hemangioma.

The product will be exclusively launched on ALI HEALTH's platform next Tuesday (13th). Both parties will also jointly launch the 'infant hemangioma care program,' encompassing expert consultations, science popularization live streams, medication guidance, charitable assistance and other services, with an aim to build a full-cycle patient-centered health management ecosystem.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.